CytomX: Easiest Money May Have Been Made, Although Pipeline Remains Compelling
CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. CTMX also now notes it plans to start combination work with CX-2051 and bevacizumab in Q1'26. Financially, CTMX holds ~$158M pro forma cash, guiding for runway through Q2'27, with further fundraising, such as using the Open Market Sales Agreement, possible.
CytomX Therapeutics: Leaning Into The Hype, But What's Next?
CytomX Therapeutics (CTMX) is highlighted as a Buy, driven by optimism for its masked antibody probody platform targeting cancer. Lead candidate CX-2051 shows promising phase 1 results in refractory colorectal cancer, with disease control in nearly all patients and confirmed responses. CTMX holds a strong financial position with $34.2 million in cash and $109.4 million in investments, supporting operations through Q2 2027.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.07 per share a year ago.
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, and falling interest rates have boosted stock prices, while M&A activity pushes valuations higher. The biotech rally could be sustainable, analysts say, with biotech firms more disciplined and increasingly profitable, while startups avoid launching premature IPOs.
CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible
CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response rate given the late stage of the colorectal cancer patients enrolled in the study. CTMX finished Q2'25 with $158.1M in cash, which it expects to last into Q2'27.
CytomX: A Fresh Start With New Drugs After Total Pipeline Failure
CytomX Therapeutics pivots to focus on CX-2051 for metastatic colorectal cancer after terminating prior clinical candidates and restructuring operations. CX-2051 shows promising early Phase 1 efficacy (28% ORR, up to 43% at highest dose) but presents notable GI toxicity risks requiring close monitoring. Financially, CTMX is well-capitalized with $158.1 million in cash, providing a cash runway into late 2027 despite ongoing operating losses.
CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Christopher W. Ogden - SVP & Chief Financial Officer Sean A.
CytomX Therapeutics: Updated Outlook For Late 2025
I remain bullish on CytomX Therapeutics due to promising pipeline developments in masked antibody-based immunotherapies for cancer. CX-2051 shows strong disease control in refractory colorectal cancer, with manageable side effects, supporting continued clinical progress. Initiation of CX-801 phase 1 trial in metastatic melanoma, combined with pembrolizumab, marks a key milestone for the pipeline.
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
CytomX Therapeutics (CTMX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
CytomX Therapeutics: Doubling Overnight On Phase 1 Data
CytomX Therapeutics' CX-2501 shows promising phase 1 results in refractory colorectal cancer, with a 27.8% objective response rate and manageable toxicity. CTMX's financial position strengthened by a $100 million stock offering, extending cash runway through 2025. CX-904 development with Amgen discontinued, but collaboration continues on a preclinical T-cell engager project.
CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) CX-2051 Phase 1 Interim Clinical Data in Advanced Colorectal Cancer May 12, 2025 8:00 AM ET Company Participants Sean McCarthy - Chairman and CEO Chris Ogden - CFO Wayne Chu - Chief Medical Officer Conference Call Participants Roger Song - Jefferies Anupam Rama - JPMorgan Peter Lawson - Barclays Robert Driscoll - Wedbush Securities Daniel Smith - H.C. Wainwright Operator Good morning, everyone, and thank you for standing by.
CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.17 per share a year ago.
